1. Home
  2. Browse
  3. National Institutes of Health
  4. PAR-25-024

PAR-25-024National Institutes of HealthR61

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

Deadline
Award ceiling
Not stated
Awards
Not stated
Posted
Oct 28, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 review criteria here, free with an account. Create free account

Summary

The purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions…

Related NIH announcements6

Other open R61 announcements on related subjects, with at least two weeks to go.

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

RFA-CA-27-001National Institutes of Health4 review criteria on file

$150k

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

PAR-25-269National Institutes of Health3 review criteria on file

$350k

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

PAR-25-158National Institutes of Health3 review criteria on fileagency framework

—

HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)

RFA-NS-25-023National Institutes of Health4 review criteria on file

$350k

Translational Neural Devices (R61/R33 - Clinical Trial Optional)

PAR-25-053National Institutes of Health3 review criteria on file

—

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

PAR-25-026National Institutes of Health3 review criteria on file

—

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 review criteria reviewers score this against, extracted from this announcement

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-057National Institutes of Health6 review criteria on file

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

Everything open from National Institutes of Health

Source record: https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.